These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 17356528)

  • 21. Alteration of gastric functions and candidate genes associated with weight reduction in response to sibutramine.
    Vazquez Roque MI; Camilleri M; Clark MM; Tepoel DA; Jensen MD; Graszer KM; Kalsy SA; Burton DD; Baxter KL; Zinsmeister AR
    Clin Gastroenterol Hepatol; 2007 Jul; 5(7):829-37. PubMed ID: 17544870
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of moderate weight loss on health-related quality of life: an analysis of combined data from 4 randomized trials of sibutramine vs placebo.
    Samsa GP; Kolotkin RL; Williams GR; Nguyen MH; Mendel CM
    Am J Manag Care; 2001 Sep; 7(9):875-83. PubMed ID: 11570021
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of weight reduction by sibutramine on female sexual function.
    Kim KK; Kang HC; Kim SS; Youn BB
    Int J Obes (Lond); 2006 May; 30(5):758-63. PubMed ID: 16404407
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Long-term Outcomes of Sibutramine Effectiveness on Weight (LOSE Weight) study: evaluating the role of drug therapy within a weight management program in a group-model health maintenance organization.
    Porter JA; Raebel MA; Conner DA; Lanty FA; Vogel EA; Gay EC; Merenich JA
    Am J Manag Care; 2004 Jun; 10(6):369-76. PubMed ID: 15209480
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Orlistat and sibutramine beyond weight loss.
    Mannucci E; Dicembrini I; Rotella F; Rotella CM
    Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):342-8. PubMed ID: 17928208
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial.
    Torp-Pedersen C; Caterson I; Coutinho W; Finer N; Van Gaal L; Maggioni A; Sharma A; Brisco W; Deaton R; Shepherd G; James P;
    Eur Heart J; 2007 Dec; 28(23):2915-23. PubMed ID: 17595194
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients.
    Kaya A; Aydin N; Topsever P; Filiz M; Oztürk A; Dağar A; Kilinç E; Ekmekcioglu C
    Biomed Pharmacother; 2004 Dec; 58(10):582-7. PubMed ID: 15589067
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Weight loss and body fat reduction under sibutramine therapy in obesity with the C825T polymorphism in the GNB3 gene.
    Hsiao DJ; Wu LS; Huang SY; Lin E
    Pharmacogenet Genomics; 2009 Sep; 19(9):730-3. PubMed ID: 19687782
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Patients with type III obesity given sibutramine 15 mg/day lose weight in amounts proportional to those in types I and II, but waist circumferences does not decrease proportionally].
    López-Alvarenga JC; Vargas JA; Schneider-Ehrenberg OP; Comuzzie AG; González J; Martínez JL
    Gac Med Mex; 2007; 143(2):109-14. PubMed ID: 17585697
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of sibutramine and orlistat on mood in obese and overweight subjects: a randomised study.
    Kiortsis DN; Tsouli S; Filippatos TD; Konitsiotis S; Elisaf MS
    Nutr Metab Cardiovasc Dis; 2008 Mar; 18(3):207-10. PubMed ID: 17570651
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term pharmacotherapy for obesity.
    Klein S
    Obes Res; 2004 Dec; 12 Suppl():163S-6S. PubMed ID: 15687412
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Who will lose weight on sibutramine and orlistat? Psychological correlates for treatment success.
    Elfhag K; Finer N; Rössner S
    Diabetes Obes Metab; 2008 Jun; 10(6):498-505. PubMed ID: 17593239
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of meal replacement on metabolic risk factors in overweight and obese subjects.
    König D; Deibert P; Frey I; Landmann U; Berg A
    Ann Nutr Metab; 2008; 52(1):74-8. PubMed ID: 18319587
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The new role of pharmacotherapy for weight reduction in obesity.
    Fernstrom MH; Fernstrom JD
    Int J Clin Pract; 2002 Nov; 56(9):683-6. PubMed ID: 12469983
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phenylethanolamine N-methyltransferase G-148A genetic variant and weight loss in obese women.
    Peters WR; MacMurry JP; Walker J; Giese RJ; Comings DE
    Obes Res; 2003 Mar; 11(3):415-9. PubMed ID: 12634439
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combining behavioral and pharmacological treatments for obesity.
    Phelan S; Wadden TA
    Obes Res; 2002 Jun; 10(6):560-74. PubMed ID: 12055334
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized trial of lifestyle modification and pharmacotherapy for obesity.
    Wadden TA; Berkowitz RI; Womble LG; Sarwer DB; Phelan S; Cato RK; Hesson LA; Osei SY; Kaplan R; Stunkard AJ
    N Engl J Med; 2005 Nov; 353(20):2111-20. PubMed ID: 16291981
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
    Derosa G; D'Angelo A; Salvadeo SA; Ferrari I; Gravina A; Fogari E; Maffioli P; Cicero AF
    Metabolism; 2008 Nov; 57(11):1552-7. PubMed ID: 18940393
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic options for modifying cardiometabolic risk factors.
    Aronne LJ
    Am J Med; 2007 Mar; 120(3 Suppl 1):S26-34. PubMed ID: 17320519
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Croatian experience with sibutramine in the treatment of obesity--multicenter prospective study.
    Stimac D; Ruzić A; Majanović SK
    Coll Antropol; 2004 Jun; 28(1):215-21. PubMed ID: 15636078
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.